Now I have a comprehensive picture. Let me write the earnings preview.# IQVIA Holdings (IQV) — Q2 2026 Earnings Preview Reporting: Tuesday, July 28, 2026, before market open

Snapshot

Last close (7/27/26)	~$213
52-week range (approx.)	~$157 (late Apr low) – ~$244 (mid-Jan high)
Consensus revenue (Q2'26)	~$4.3B (~7% y/y)
Consensus adj. EPS (Q2'26)	~$3.01
Company Q2 guidance (given 5/5/26)	Revenue $4.28B–$4.34B (+6.5%–8.0% y/y); Adj. EBITDA $955M–$975M (+4.9%–7.1%); Adj. diluted EPS $2.98–$3.08 (+6.0%–9.6%)

The stock has staged a big round trip: it fell from the low-$240s in January into the $160s by late February/April on macro and pharma-policy jitters, then rallied hard off the April low (~$157) to the low/mid-$200s heading into this print — up roughly 8% over the past month alone. Shares enter the quarter with an average sell-side price target near $222–$230, implying the market is pricing in continued, but not dramatic, upside from a beat.

What happened last quarter (the setup)

Q1 2026 was a clean beat-and-raise. Total revenue for the first quarter exceeded the high end of guidance, up 8.4% on a reported basis, 6% at constant currency, and adjusted diluted EPS of $2.90 also exceeded the high end of guidance, increasing 7.4% year-over-year. Management highlighted broad-based acceleration: year-over-year, organic revenue growth in Commercial Solutions doubled and organic revenue growth in R&DS tripled.

Key underlying trends to track this quarter: - Backlog/bookings momentum: Backlog reached a new record of $34.2 billion at the end of the quarter, with $8.9 billion expected to convert to revenue in the next 12 months, representing nearly 8% growth year-over-year versus recast prior-year numbers. R&DS net new bookings were $2.5B, and management was adamant that a book-to-bill of 1.04x understated true demand because reimbursed expenses/pass-through bookings were well below historical averages, which mechanically depresses the headline book-to-bill without affecting margins (per the earnings release language). Watch whether Q2 book-to-bill normalizes and whether service-fee bookings growth (ex-pass-throughs) continues. - AI as a demand driver, not a disruptor: Management pushed back hard on Street fears that AI would cannibalize CRO/commercial services revenue. "We have 192 agents deployed in the field, covering 64 use cases across both our Commercial Solutions and R&DS businesses. 19 of the top 20 pharma companies are already using IQVIA agents in some of their workflows." CEO Ari Bousbib specifically noted "the number of trials that we lost to anyone using [an AI tool]... is exactly 0" and argued AI-driven discovery is expanding pharma pipelines, which should increase future trial volume. - Segment reporting change: IQVIA moved to a simplified two-segment structure (Commercial Solutions and R&D Solutions) effective January 1, 2026, with prior periods recast — keep comparisons on a recast, like-for-like basis. - Capital allocation: The board added $2 billion to the buyback authorization in May (bringing remaining authorization to $3.2B), and IQVIA repurchased $552 million of stock in Q1 alone. In June, a subsidiary issued €950 million of 4.625% senior notes due 2033 to refinance existing debt — a sign management is terming out debt while leverage sits around 3.6x net debt/EBITDA. No dividend is paid, and buybacks remain the primary capital-return lever.

What to watch this quarter

1. Revenue/EPS vs. guidance: The bar is $4.28–$4.34B revenue and $2.98–$3.08 adjusted EPS. Consensus (~$4.3B revenue, ~$3.01 EPS) sits mid-guidance, and IQVIA has topped Street EPS estimates for four straight quarters (average surprise ~1.6%), so the bar for a "beat" is real but not extreme.
2. Segment organic growth trajectory: Q1 organic growth was 3% in R&DS (vs. 1% a year ago) and 5% in Commercial Solutions (vs. ~2.5% a year ago). Investors will want confirmation that this acceleration continued into Q2 rather than being a one-quarter anomaly, especially in Analytics & Consulting (best growth in 3 years in Q1) and Patient Solutions (double-digit growth).
3. Large-pharma demand normalization vs. EVP funding: Management described large pharma as "more constructive" but still more deliberate than pre-turmoil levels, while emerging/biotech (EVP) funding surged to $25 billion in Q1, almost double the funding in Q1 2025. Commentary on whether that funding is translating into RFPs/awards will matter for 2027 growth visibility.
4. Margins: Q1 adjusted EBITDA margin contracted ~60bp y/y, but management attributed this entirely to non-operational FX/pass-through mix, saying "operationally, we expanded margins actually quite significantly in the quarter" and expects reported margins to "flip to positive as we progress through the year" as the FX tailwind moderates and productivity programs continue. Q2 is a good test of that call.
5. Free cash flow / buybacks: Q1 FCF of $491M was 100% of adjusted net income, up 15% y/y. With $3.2B of buyback capacity and fresh debt issuance to manage refinancing, watch for updated repurchase pace and any change in leverage targets (net leverage was 3.62x LTM EBITDA at Q1-end).
6. Peer read-throughs: Among life-sciences tools/services peers that have already reported this cycle, Medpace beat estimates (+17.2% revenue growth) and traded up sharply, while West Pharmaceutical Services beat revenue (+13.8%) but traded down — a reminder that beats alone aren't enough; guidance/margin commentary is driving stock reaction this season.

Risks/bear case

• The prior 3–4 years of "industry turmoil" — post-COVID budget deflation, IRA drug pricing, and Trump-era tariff/MFN policy uncertainty — constrained large-pharma discretionary spend, and management itself says the industry hasn't fully returned to pre-turmoil decision-making speed.
• No dividend; capital return is entirely via buybacks.
• Current ratio has run below 1.0 for multiple quarters (current liabilities exceed current assets), a liquidity structure some analysts flag as a watch item even though cash flow generation remains strong.
• The quarterly book-to-bill metric remains noisy and mix-dependent (FSP vs. full-service, pass-through-heavy vs. light trial mixes), which management concedes is a poor short-term growth predictor but which the market still fixates on.

Bottom line

IQV heads into Q2 with genuine momentum — record backlog, accelerating organic growth in both segments, an AI narrative that's shifted from perceived threat to demonstrated tailwind, and a stock that's recovered most of its 2026 drawdown. Guidance (already raised once this year on EPS) sets a moderate bar that the company has consistently cleared. The key swing factors for the stock's reaction are less about whether revenue/EPS lands in-guidance (likely) and more about: (1) whether book-to-bill and net service-fee bookings show continued sequential improvement, (2) whether margin commentary confirms the promised second-half inflection, and (3) any incremental color on large-pharma decision-making pace and EVP funding conversion into bookings.